GOVX · GeoVax Labs, Inc.

GeoVax Labs, Inc. is a clinical-stage biotechnology company focused on developing vaccines and immunotherapies for infectious diseases and solid tumor cancers. The company's primary near-term strategic priority is GEO-MVA, a vaccine candidate for mpox and smallpox, which it plans to advance directly to a Phase 3 clinical trial in the second half of 2026 following scientific advice from the EMA. This program aims to address a documented global supply constraint for orthopoxvirus vaccines. Additionally, the company is developing Gedeptin for solid tumors and GEO-CM04S1, a next-generation COVID-19 vaccine. The company operates in a highly competitive market against large pharmaceutical companies with substantially greater resources.

Financially, the company is in a pre-revenue stage concerning product sales, with revenue derived solely from government contracts. For the year ended December 31, 2025, the company reported a net loss of approximately $21.5 million and revenue of $2.5 million, a decrease from the prior year primarily due to the termination of a BARDA contract in April 2025. The company has a history of operating losses and has received a 'going concern' opinion from its auditors. As of December 31, 2025, the company held $3.1 million in cash and equivalents, which management believes is sufficient to fund operations only into the mid-second quarter of 2026. This liquidity constraint highlights the critical need for additional financing to continue operations and advance clinical programs.

The current registration statement covers the resale of 1,269,316 shares of common stock by selling stockholders issuable upon the exercise of March 2026 Common Warrants. The company will not receive any proceeds from the sale of these shares by the selling stockholders; however, it will receive proceeds from any cash exercise of the warrants. The selling stockholders may sell shares at prevailing market prices or negotiated prices. This offering structure results in potential dilution for existing shareholders without providing direct capital infusion to the company from the resale of shares, though warrant exercises would provide some capital.

Key risks specific to GeoVax include its ability to continue as a going concern, the need for substantial additional funding, and the early-stage nature of its product candidates which have not been proven in clinical trials or approved for sale. The company also faces significant delisting risk from Nasdaq due to proposed new market value requirements and compliance with minimum bid price rules, having recently executed a reverse stock split in January 2026. The termination of the BARDA contract for the GEO-CM04S1 program represents a setback in development funding and partnership. Management, led by CEO David Dodd, has extensive industry experience but faces the challenge of securing necessary capital to advance the pipeline through clinical development and regulatory approval.